ArticleBreast cancer (Tokyo, Japan)2026
Long-term outcomes of adjuvant radiation in elderly Asians with early stage IIA breast cancer after breast-conserving surgery: a population-based study.
Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe benefit of postoperative radiotherapy (RT) for Asian older patients with early-stage breast cancer remains unclear. This study aimed to investigate the use of adjuvant RT in clinical practice to treat elderly Asians by evaluating relevant clinical factors.
methodsA total of 1,180 older adults with American Joint Committee on Cancer stage T2N0 breast cancer with tumors ≤ 3 cm were enrolled from the Taiwan Cancer Registry between January 2011 and December 2020. We used multivariable Cox proportional hazards models to control for clinical factors and propensity score matching for sensitivity analysis. Overall survival (OS) and recurrence-free survival (RFS) were estimated using the Kaplan–Meier method and the log-rank test.
resultsAmong the patients aged > 70 years who received hormone therapy, RFS differed significantly between those who received adjuvant RT and those who did not (hazard ratio [HR] = 0.115, p = 0.01). The 5-year OS rate was 93% and 76% for those with and without adjuvant RT, respectively (HR = 0.34, 95% confidence interval [CI], 0.26–0.46, p < 0.001). After covariate adjustment, the OS advantage from RT was significant both for patients aged 65–70 years (HR = 0.284, 95% CI, 0.155–0.520) and those aged > 70 years (HR = 0.512, 95% CI, 0.358–0.734).
conclusionsRFS was significantly improved by adjuvant RT in patients aged > 70 years with hormone-positive tumors. Furthermore, OS advantage was observed in Asian older adults with early breast cancer who received RT following conservative breast surgery. Adding RT to adjuvant systemic therapy is beneficial and well-tolerable in older Asian patients with small T2 tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.